What is HC Wainwright's Estimate for Kamada FY2025 Earnings?

Key Points

• HC Wainwright has raised its FY2025 earnings per share (EPS) estimate for Kamada Ltd. to $0.47, up from a previous estimate of $0.39, indicating positive expectations for the biotechnology company.
• In addition to FY2025, HC Wainwright projected Q4 2025 earnings at $0.17 EPS and continuous growth with FY2028 earnings estimated at $0.78 EPS.
• Kamada's stock recently traded at $7.28 and has a market cap of $418.39 million, reflecting slight volatility as it nears its 1-year high of $9.15.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities researchers at HC Wainwright upped their FY2025 earnings estimates for shares of Kamada in a research note issued to investors on Thursday, August 14th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $0.47 per share for the year, up from their previous estimate of $0.39. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada's Q4 2025 earnings at $0.17 EPS, FY2026 earnings at $0.50 EPS, FY2027 earnings at $0.71 EPS and FY2028 earnings at $0.78 EPS.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.09 by $0.04. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The firm had revenue of $44.75 million during the quarter, compared to analysts' expectations of $158.59 million.

Other equities analysts also recently issued reports about the company. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Sidoti upgraded Kamada to a "hold" rating in a research report on Thursday, May 8th. Finally, Benchmark reaffirmed a "buy" rating and set a $15.00 price target on shares of Kamada in a research note on Thursday, May 15th.

Kamada Price Performance

Shares of KMDA stock traded down $0.18 during midday trading on Friday, reaching $7.17. 90,948 shares of the company traded hands, compared to its average volume of 49,571. The firm's 50 day simple moving average is $7.47 and its two-hundred day simple moving average is $7.07. The firm has a market cap of $412.35 million, a PE ratio of 21.09, a price-to-earnings-growth ratio of 0.78 and a beta of 0.93. Kamada has a 1-year low of $5.17 and a 1-year high of $9.15.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KMDA. Geode Capital Management LLC grew its holdings in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after buying an additional 1,549 shares during the last quarter. Huntleigh Advisors Inc. boosted its stake in shares of Kamada by 3.9% during the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company's stock valued at $1,052,000 after acquiring an additional 5,151 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Kamada by 3.1% during the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company's stock valued at $2,053,000 after acquiring an additional 7,925 shares during the last quarter. NewEdge Advisors LLC increased its position in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 8,260 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Kamada in the 4th quarter valued at about $67,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.